Skip to main content
Erschienen in: Current Cardiology Reports 4/2024

26.02.2024 | Myocardial Disease (A Abbate and M Merlo, Section Editors)

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention

verfasst von: Silvia Moscardelli, Reza Masoomi, Pedro Villablanca, Ahmad Jabri, Ankitkumar K. Patel, Francesco Moroni, Lorenzo Azzalini

Erschienen in: Current Cardiology Reports | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review will focus on the indications of mechanical circulatory support (MCS) for high-risk percutaneous coronary intervention (PCI) and then analyze in detail all MCS devices available to the operator, evaluating their mechanisms of action, pros and cons, contraindications, and clinical data supporting their use.

Recent Findings

Over the last decade, the interventional cardiology arena has witnessed an increase in the complexity profile of the patients and lesions treated in the catheterization laboratory. Patients with significant comorbidity burden, left ventricular dysfunction, impaired hemodynamics, and/or complex coronary anatomy often cannot tolerate extensive percutaneous revascularization. Therefore, a variety of MCS devices have been developed and adopted for high-risk PCI.

Summary

Despite the variety of MCS available to date, a detailed characterization of the patient requiring MCS is still lacking. A precise selection of patients who can benefit from MCS support during high-risk PCI and the choice of the most appropriate MCS device in each case are imperative to provide extensive revascularization and improve patient outcomes. Several new devices are being tested in early feasibility studies and randomized clinical trials and the experience gained in this context will allow us to provide precise answers to these questions in the coming years.
Literatur
1.
Zurück zum Zitat Bortnick AE, Epps KC, Selzer F, Anwaruddin S, Marroquin OC, Srinivas V, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol. 2014;113:573–9.CrossRefPubMed Bortnick AE, Epps KC, Selzer F, Anwaruddin S, Marroquin OC, Srinivas V, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol. 2014;113:573–9.CrossRefPubMed
2.
Zurück zum Zitat Protty M, Sharp ASP, Gallagher S, Farooq V, Spratt JC, Ludman P, et al. Defining percutaneous coronary intervention complexity and risk: an analysis of the United Kingdom BCIS database 2006–2016. JACC Cardiovasc Interv. 2022;15:39–49.CrossRefPubMed Protty M, Sharp ASP, Gallagher S, Farooq V, Spratt JC, Ludman P, et al. Defining percutaneous coronary intervention complexity and risk: an analysis of the United Kingdom BCIS database 2006–2016. JACC Cardiovasc Interv. 2022;15:39–49.CrossRefPubMed
3.
Zurück zum Zitat Khandelwal G, Spirito A, Tanner R, Koshy AN, Sartori S, Salehi N, et al. Validation of UK-BCIS CHIP score to predict 1-year outcomes in a contemporary united states population. JACC Cardiovasc Interv. 2023;16:1011–20.CrossRefPubMed Khandelwal G, Spirito A, Tanner R, Koshy AN, Sartori S, Salehi N, et al. Validation of UK-BCIS CHIP score to predict 1-year outcomes in a contemporary united states population. JACC Cardiovasc Interv. 2023;16:1011–20.CrossRefPubMed
4.
Zurück zum Zitat Nayyar M, Donovan KM, Khouzam RN. When more is not better—appropriately excluding patients from mechanical circulatory support therapy. Ann Transl Med. 2018;6:9–9.CrossRefPubMedPubMedCentral Nayyar M, Donovan KM, Khouzam RN. When more is not better—appropriately excluding patients from mechanical circulatory support therapy. Ann Transl Med. 2018;6:9–9.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kim SH, Baumann S, Behnes M, Borggrefe M, Akin I. Patient selection for protected percutaneous coronary intervention: Who benefits the most? Cardiol Clin. W.B. Saunders; 2020:507–16. Kim SH, Baumann S, Behnes M, Borggrefe M, Akin I. Patient selection for protected percutaneous coronary intervention: Who benefits the most? Cardiol Clin. W.B. Saunders; 2020:507–16.
6.
Zurück zum Zitat Atkinson TM, Ohman EM, O’neill WW, Rab T, Cigarroa JE. Statement from the interventional council of the ACC a practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention an interventional perspective. JACC: Cardiovasc Interv. 2016;9:871–83.PubMed Atkinson TM, Ohman EM, O’neill WW, Rab T, Cigarroa JE. Statement from the interventional council of the ACC a practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention an interventional perspective. JACC: Cardiovasc Interv. 2016;9:871–83.PubMed
7.
Zurück zum Zitat Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e21–129.CrossRefPubMed Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e21–129.CrossRefPubMed
8.
Zurück zum Zitat •• Zeitouni M, Marquis-Gravel G, Smilowitz NR, Zakroysky P, Wojdyla DM, Amit AP, et al. Prophylactic mechanical circulatory support use in elective percutaneous coronary intervention for patients with stable coronary artery disease. Circ Cardiovasc Interv. 2022;15:E011534. Findings from this study suggest that the use of prophylactic MCS has increased over time for elective PCI in patients with stable coronary artery disease. Intra-aortic balloon pump was associated with higher major adverse cardiac events but lower risk of procedural complications compared with other MCS.CrossRefPubMed •• Zeitouni M, Marquis-Gravel G, Smilowitz NR, Zakroysky P, Wojdyla DM, Amit AP, et al. Prophylactic mechanical circulatory support use in elective percutaneous coronary intervention for patients with stable coronary artery disease. Circ Cardiovasc Interv. 2022;15:E011534. Findings from this study suggest that the use of prophylactic MCS has increased over time for elective PCI in patients with stable coronary artery disease. Intra-aortic balloon pump was associated with higher major adverse cardiac events but lower risk of procedural complications compared with other MCS.CrossRefPubMed
9.
Zurück zum Zitat Werner N, Akin I, Al-Rashid F, Bauer T, Ibrahim K, Karatolios K, et al. Expertenkonsensus zum praktischen Einsatz von Herzkreislaufunterstützungssystemen bei Hochrisiko-Koronarinterventionen. Kardiologe. 2017;11:460–72.CrossRef Werner N, Akin I, Al-Rashid F, Bauer T, Ibrahim K, Karatolios K, et al. Expertenkonsensus zum praktischen Einsatz von Herzkreislaufunterstützungssystemen bei Hochrisiko-Koronarinterventionen. Kardiologe. 2017;11:460–72.CrossRef
10.
Zurück zum Zitat Atkinson TM, Ohman EM, O’Neill WW, Rab T, Cigarroa JE. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9:871–83.CrossRefPubMed Atkinson TM, Ohman EM, O’Neill WW, Rab T, Cigarroa JE. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9:871–83.CrossRefPubMed
11.
Zurück zum Zitat Kearney KE, Mccabe JM, Riley RF. Patient selection and procedural strategy are key in treating this evolving patient population. Hemodynamic Support for High-Risk PCI. Cardiac Interv Today. 2019;13:44–8. Kearney KE, Mccabe JM, Riley RF. Patient selection and procedural strategy are key in treating this evolving patient population. Hemodynamic Support for High-Risk PCI. Cardiac Interv Today. 2019;13:44–8.
12.
Zurück zum Zitat Grodin JL, Mullens W, Dupont M, Wu Y, Taylor DO, Starling RC, et al. Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. Eur J Heart Fail. 2015;17:689–96.CrossRefPubMed Grodin JL, Mullens W, Dupont M, Wu Y, Taylor DO, Starling RC, et al. Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. Eur J Heart Fail. 2015;17:689–96.CrossRefPubMed
13.
Zurück zum Zitat Papaioannou TG, Stefanadis C. Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. ASAIO J. 2005;51:296–300.CrossRefPubMed Papaioannou TG, Stefanadis C. Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. ASAIO J. 2005;51:296–300.CrossRefPubMed
14.
Zurück zum Zitat Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention a randomized controlled trial. J Am Med Assoc. 2010;308:867–74. Available from: https://jamanetwork.com/ Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention a randomized controlled trial. J Am Med Assoc. 2010;308:867–74. Available from: https://​jamanetwork.​com/​
15.
Zurück zum Zitat Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): A randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013;127:207–12.CrossRefPubMed Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): A randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013;127:207–12.CrossRefPubMed
16.
Zurück zum Zitat Glazier JJ, Kaki A. The impella device: Historical background, clinical applications and future directions. Int J Angiol. 2019;28:118–23.CrossRefPubMed Glazier JJ, Kaki A. The impella device: Historical background, clinical applications and future directions. Int J Angiol. 2019;28:118–23.CrossRefPubMed
17.
Zurück zum Zitat Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol. 2015;65:e7–26.CrossRefPubMed Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol. 2015;65:e7–26.CrossRefPubMed
18.
Zurück zum Zitat Van Edom CJ, Gramegna M, Baldetti L, Beneduce A, Castelein T, Dauwe D, et al. Management of bleeding and hemolysis during percutaneous microaxial flow pump support: a practical approach. JACC Cardiovasc Interv. 2023;16:1707–20.CrossRefPubMed Van Edom CJ, Gramegna M, Baldetti L, Beneduce A, Castelein T, Dauwe D, et al. Management of bleeding and hemolysis during percutaneous microaxial flow pump support: a practical approach. JACC Cardiovasc Interv. 2023;16:1707–20.CrossRefPubMed
19.
Zurück zum Zitat Dixon SR, Henriques JPS, Mauri L, Sjauw K, Civitello A, Kar B, et al. A prospective feasibility trial investigating the use of the impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial). JACC Cardiovasc Interv. 2009;2:91–6.CrossRefPubMed Dixon SR, Henriques JPS, Mauri L, Sjauw K, Civitello A, Kar B, et al. A prospective feasibility trial investigating the use of the impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial). JACC Cardiovasc Interv. 2009;2:91–6.CrossRefPubMed
20.
Zurück zum Zitat Ww O, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. Interventional cardiology a prospective, randomized clinical trial of hemodynamic support with impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention The PROTECT II Study. Circulation. 2012;126:1717–27. https://doi.org/10.1161/CIRCULATIONAHA.CrossRef Ww O, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. Interventional cardiology a prospective, randomized clinical trial of hemodynamic support with impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention The PROTECT II Study. Circulation. 2012;126:1717–27. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.CrossRef
21.
Zurück zum Zitat Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessen BE, Dixon SR, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014;113:222–8.CrossRefPubMed Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessen BE, Dixon SR, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014;113:222–8.CrossRefPubMed
22.
Zurück zum Zitat Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, et al. Supported high-risk percutaneous coronary intervention with the impella 2.5 device. The Europella Registry. J Am Coll Cardiol. 2009;54:2430–4.CrossRefPubMed Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, et al. Supported high-risk percutaneous coronary intervention with the impella 2.5 device. The Europella Registry. J Am Coll Cardiol. 2009;54:2430–4.CrossRefPubMed
23.
Zurück zum Zitat Maini B, Naidu SS, Mulukutla S, Kleiman N, Schreiber T, Wohns D, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: The USpella Registry. Catheter Cardiovasc Interv. 2012;80:717–25.CrossRefPubMed Maini B, Naidu SS, Mulukutla S, Kleiman N, Schreiber T, Wohns D, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: The USpella Registry. Catheter Cardiovasc Interv. 2012;80:717–25.CrossRefPubMed
24.
Zurück zum Zitat • O’Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, et al. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. Am Heart J. 2022;248:139–49. The PROTECT III study demonstrates improved completeness of revascularization, less bleeding, and improved 90-day clinical outcomes compared to matched patients from the PROTECT II trial (Impella-supported high-risk percutaneous coronary intervention among patients with severely depressed LVEF.CrossRefPubMed • O’Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, et al. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. Am Heart J. 2022;248:139–49. The PROTECT III study demonstrates improved completeness of revascularization, less bleeding, and improved 90-day clinical outcomes compared to matched patients from the PROTECT II trial (Impella-supported high-risk percutaneous coronary intervention among patients with severely depressed LVEF.CrossRefPubMed
25.
Zurück zum Zitat Afana M, Altawil M, Basir M, Alqarqaz M, Alaswad K, Eng M, et al. Transcaval access for the emergency delivery of 5.0 liters per minute mechanical circulatory support in cardiogenic shock. Catheter Cardiovasc Interv. 2021;97:555–64.CrossRefPubMed Afana M, Altawil M, Basir M, Alqarqaz M, Alaswad K, Eng M, et al. Transcaval access for the emergency delivery of 5.0 liters per minute mechanical circulatory support in cardiogenic shock. Catheter Cardiovasc Interv. 2021;97:555–64.CrossRefPubMed
26.
Zurück zum Zitat McCabe JM, Kaki AA, Pinto DS, Kirtane AJ, Nicholson WJ, Grantham JA, et al. Percutaneous axillary access for placement of microaxial ventricular support devices: The axillary access registry to monitor safety (ARMS). Circ Cardiovasc Interv. 2021;14:e009657.CrossRefPubMed McCabe JM, Kaki AA, Pinto DS, Kirtane AJ, Nicholson WJ, Grantham JA, et al. Percutaneous axillary access for placement of microaxial ventricular support devices: The axillary access registry to monitor safety (ARMS). Circ Cardiovasc Interv. 2021;14:e009657.CrossRefPubMed
27.
Zurück zum Zitat Azzalini L, Condos G, Kearney KE, Lombardi WL, McCabe JM. Mechanical circulatory support via percutaneous transcarotid access for high-risk percutaneous coronary intervention. JACC Cardiovasc Interv. 2023;16:106–8.CrossRefPubMed Azzalini L, Condos G, Kearney KE, Lombardi WL, McCabe JM. Mechanical circulatory support via percutaneous transcarotid access for high-risk percutaneous coronary intervention. JACC Cardiovasc Interv. 2023;16:106–8.CrossRefPubMed
28.
Zurück zum Zitat Upadhyay R, Alrayes H, Arno S, Kaushik M, Basir MB. Current landscape of temporary percutaneous mechanical circulatory support technology. US Cardiol Rev. 2021;15:15-e21.CrossRef Upadhyay R, Alrayes H, Arno S, Kaushik M, Basir MB. Current landscape of temporary percutaneous mechanical circulatory support technology. US Cardiol Rev. 2021;15:15-e21.CrossRef
29.
Zurück zum Zitat Kovacic JC, Nguyen HT, Karajgikar R, Sharma SK, Kini AS. The impella recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv. 2013;82:E28-37.CrossRefPubMedPubMedCentral Kovacic JC, Nguyen HT, Karajgikar R, Sharma SK, Kini AS. The impella recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv. 2013;82:E28-37.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Gandhi KD, Moras EC, Niroula S, Lopez PD, Aggarwal D, Bhatia K, et al. Left ventricular unloading with impella versus IABP in patients with VA-ECMO: a systematic review and meta-analysis. Am J Cardiol. 2023;208:53–9.CrossRefPubMed Gandhi KD, Moras EC, Niroula S, Lopez PD, Aggarwal D, Bhatia K, et al. Left ventricular unloading with impella versus IABP in patients with VA-ECMO: a systematic review and meta-analysis. Am J Cardiol. 2023;208:53–9.CrossRefPubMed
31.
Zurück zum Zitat Chiang M, Gonzalez PE, Basir MB, O’Neill BP, Lee J, Frisoli T, et al. Modified Transcaval left atrial venoarterial extracorporeal membrane oxygenation without preplanning contrast CT: Step-by-step guide. JACC Cardiovasc Interv. 2022;15:e181–5.CrossRefPubMed Chiang M, Gonzalez PE, Basir MB, O’Neill BP, Lee J, Frisoli T, et al. Modified Transcaval left atrial venoarterial extracorporeal membrane oxygenation without preplanning contrast CT: Step-by-step guide. JACC Cardiovasc Interv. 2022;15:e181–5.CrossRefPubMed
33.
Zurück zum Zitat Bai M, Lu A, Pan C, Hu S, Qu W, Zhao J, et al. Veno-arterial extracorporeal membrane oxygenation in elective high-risk percutaneous coronary interventions. Front Med (Lausanne). 2022;9. Bai M, Lu A, Pan C, Hu S, Qu W, Zhao J, et al. Veno-arterial extracorporeal membrane oxygenation in elective high-risk percutaneous coronary interventions. Front Med (Lausanne). 2022;9.
34.
Zurück zum Zitat Shaukat A, Hryniewicz-Czeneszew K, Sun B, Mudy K, Wilson K, Tajti P, et al. Outcomes of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience and review of the literature. J Invasive Cardiol. 2018;30:456–60.PubMed Shaukat A, Hryniewicz-Czeneszew K, Sun B, Mudy K, Wilson K, Tajti P, et al. Outcomes of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience and review of the literature. J Invasive Cardiol. 2018;30:456–60.PubMed
35.
Zurück zum Zitat van den Brink FS, Meijers TA, Hofma SH, van Boven AJ, Nap A, Vonk A, et al. Prophylactic veno-arterial extracorporeal membrane oxygenation in patients undergoing high-risk percutaneous coronary intervention. Neth Hear J. 2020;28:139–44.CrossRef van den Brink FS, Meijers TA, Hofma SH, van Boven AJ, Nap A, Vonk A, et al. Prophylactic veno-arterial extracorporeal membrane oxygenation in patients undergoing high-risk percutaneous coronary intervention. Neth Hear J. 2020;28:139–44.CrossRef
36.
Zurück zum Zitat Tomasello SD, Boukhris M, Ganyukov V, Galassi AR, Shukevich D, Haes B, et al. Outcome of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience. Heart and Lung: Journal of Acute and Critical Care. 2015;44:309–13.CrossRefPubMed Tomasello SD, Boukhris M, Ganyukov V, Galassi AR, Shukevich D, Haes B, et al. Outcome of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience. Heart and Lung: Journal of Acute and Critical Care. 2015;44:309–13.CrossRefPubMed
37.
Zurück zum Zitat Samol A, Schmidt S, Zeyse M, Wiemer M, Luani B. High-risk PCI under support of a pulsatile left ventricular assist device – First German experience with the iVAC2L system. Int J Cardiol. 2019;297:30–5.CrossRefPubMed Samol A, Schmidt S, Zeyse M, Wiemer M, Luani B. High-risk PCI under support of a pulsatile left ventricular assist device – First German experience with the iVAC2L system. Int J Cardiol. 2019;297:30–5.CrossRefPubMed
38.
Zurück zum Zitat Uil CAD, Daemen J, Lenzen MJ, Maugenest AM, Joziasse L, Van Geuns RJ, et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12:1689–96.CrossRef Uil CAD, Daemen J, Lenzen MJ, Maugenest AM, Joziasse L, Van Geuns RJ, et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12:1689–96.CrossRef
39.
Zurück zum Zitat De Maria GL, Garcia-Garcia HM, Scarsini R, Finn A, Sato Y, Virmani R, et al. Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. Oxford University Press; 2021:687–97. De Maria GL, Garcia-Garcia HM, Scarsini R, Finn A, Sato Y, Virmani R, et al. Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. Oxford University Press; 2021:687–97.
40.
Zurück zum Zitat Van de Hoef TP, Nolte F, Delewi R, Henriques JPS, Spaan JAE, Tijssen JGP, et al. Intracoronary hemodynamic effects of pressure-controlled intermittent coronary sinus occlusion (PICSO): results from the First-In-Man Prepare PICSO Study. J Interv Cardiol. 2012;25:549–56.CrossRefPubMed Van de Hoef TP, Nolte F, Delewi R, Henriques JPS, Spaan JAE, Tijssen JGP, et al. Intracoronary hemodynamic effects of pressure-controlled intermittent coronary sinus occlusion (PICSO): results from the First-In-Man Prepare PICSO Study. J Interv Cardiol. 2012;25:549–56.CrossRefPubMed
41.
Zurück zum Zitat Azzalini L, Montorfano M, Latib A, Colombo A. High-risk left main percutaneous coronary intervention supported by pressure-controlled intermittent coronary sinus occlusion. EuroIntervention. 2016;12:e1437–e1437.CrossRefPubMed Azzalini L, Montorfano M, Latib A, Colombo A. High-risk left main percutaneous coronary intervention supported by pressure-controlled intermittent coronary sinus occlusion. EuroIntervention. 2016;12:e1437–e1437.CrossRefPubMed
42.
Zurück zum Zitat Williams MJ, Dow CJ, Newell JB, Palacios IF, Picard MH. Prevalence and timing of regional myocardial dysfunction after rotational coronary atherectomy. J Am Coll Cardiol. 1996;28:861–9.CrossRefPubMed Williams MJ, Dow CJ, Newell JB, Palacios IF, Picard MH. Prevalence and timing of regional myocardial dysfunction after rotational coronary atherectomy. J Am Coll Cardiol. 1996;28:861–9.CrossRefPubMed
43.
Zurück zum Zitat Zein R, Patel C, Mercado-Alamo A, Schreiber T, Kaki A. A review of the impella devices. Interv Cardiol: Rev Res Resour. 2022;17:17–e05.CrossRef Zein R, Patel C, Mercado-Alamo A, Schreiber T, Kaki A. A review of the impella devices. Interv Cardiol: Rev Res Resour. 2022;17:17–e05.CrossRef
44.
Zurück zum Zitat Smith L, Peters A, Mazimba S, Ragosta M, Taylor AM. Outcomes of patients with cardiogenic shock treated with TandemHeart® percutaneous ventricular assist device: Importance of support indication and definitive therapies as determinants of prognosis. Catheter Cardiovasc Interv. 2018;92:1173–81.CrossRefPubMed Smith L, Peters A, Mazimba S, Ragosta M, Taylor AM. Outcomes of patients with cardiogenic shock treated with TandemHeart® percutaneous ventricular assist device: Importance of support indication and definitive therapies as determinants of prognosis. Catheter Cardiovasc Interv. 2018;92:1173–81.CrossRefPubMed
45.
Zurück zum Zitat Richardson ASC, Tonna JE, Nanjayya V, Nixon P, Abrams DC, Raman L. Extracorporeal cardiopulmonary resuscitation in adults. Interim guideline consensus statement from the extracorporeal life support organization. ASAIO J. 2021;67:221–8.CrossRefPubMed Richardson ASC, Tonna JE, Nanjayya V, Nixon P, Abrams DC, Raman L. Extracorporeal cardiopulmonary resuscitation in adults. Interim guideline consensus statement from the extracorporeal life support organization. ASAIO J. 2021;67:221–8.CrossRefPubMed
Metadaten
Titel
Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention
verfasst von
Silvia Moscardelli
Reza Masoomi
Pedro Villablanca
Ahmad Jabri
Ankitkumar K. Patel
Francesco Moroni
Lorenzo Azzalini
Publikationsdatum
26.02.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 4/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02029-2

Weitere Artikel der Ausgabe 4/2024

Current Cardiology Reports 4/2024 Zur Ausgabe

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

The Global Epidemic of Metabolic Fatty Liver Disease

Management of Acute Coronary Syndromes (H Jneid, Section Editor)

Updates on Non-Statin LDL-Lowering Therapy

Ischemic Heart Disease (D Mukherjee, Section Editor)

Update on the Role of Colchicine in Cardiovascular Disease

Peripheral Vascular Disease (S Kinlay, Section Editor)

Open Surgical Therapy for Peripheral Artery Disease

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

LDL-Cholesterin kann ApoB als Risikomarker nicht ersetzen

16.05.2024 Hypercholesterinämie Nachrichten

Apolipoprotein B (ApoB) ist ein genauer Risikomarker für atherosklerotisch bedingte Erkrankungen. Aber das LDL-Cholesterin doch auch – lohnt sich also die ApoB-Messung überhaupt?

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.